9ca1da07-df79-4bbf-be81-0ef9de95ab0c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- DNA_REPAIR+0.300
- SPERMATOGENESIS+0.300
- GLYCOLYSIS+0.200
- MITOTIC_SPINDLE+0.200
- MTORC1_SIGNALING+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- APOPTOSIS-0.300
- COAGULATION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_R439VVPK | medulloblastoma | — | 0.908 |
| 2 | SRR10899976 | — | — | 0.907 |
| 3 | C3N-03076 | — | cohortMD1 | 0.907 |
| 4 | BS_HE57E1RP | medulloblastoma | — | 0.905 |
| 5 | BS_81SP2HX4 | medulloblastoma | — | 0.902 |
| 6 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.899 |
| 7 | BS_FKDQJJB5 | medulloblastoma | — | 0.893 |
| 8 | BS_AHEFXG7W | medulloblastoma | — | 0.890 |
| 9 | SRR15069603 | — | — | 0.889 |
| 10 | SRR6013537 | — | cohortA3 | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |